Chongqing Genrix Biopharmaceutical (688443.SH): Sailiqi Monoclonal Antibody Injection Included in 2025 National Reimbursement Drug List

Stock News12-07

Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SH) announced that its self-developed Sailiqi Monoclonal Antibody Injection (Jinlixi) has been successfully included in the National Reimbursement Drug List (NRDL) for basic medical insurance, maternity insurance, and work-related injury insurance. The updated NRDL will take effect on January 1, 2026.

Sailiqi Monoclonal Antibody Injection is a company-developed recombinant fully human anti-IL-17A monoclonal antibody, classified as a Class I therapeutic biological product. It targets IL-17A, specifically binding to the IL-17A protein in serum and blocking its interaction with IL-17RA, thereby inhibiting the onset and progression of inflammation. This mechanism provides therapeutic effects for autoimmune diseases such as plaque psoriasis and radiographic axial spondyloarthritis associated with IL-17A overexpression.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199986475?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 16:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199986475","market":"nz","top_or_hot":-1,"title":"Chongqing Genrix Biopharmaceutical (688443.SH): Sailiqi Monoclonal Antibody Injection Included in 2025 National Reimbursement Drug List","media":"Stock News","content":"<p>Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SH) announced that its self-developed Sailiqi Monoclonal Antibody Injection (Jinlixi) has been successfully included in the National Reimbursement Drug List (NRDL) for basic medical insurance, maternity insurance, and work-related injury insurance. The updated NRDL will take effect on January 1, 2026.</p>\n<p>Sailiqi Monoclonal Antibody Injection is a company-developed recombinant fully human anti-IL-17A monoclonal antibody, classified as a Class I therapeutic biological product. It targets IL-17A, specifically binding to the IL-17A protein in serum and blocking its interaction with IL-17RA, thereby inhibiting the onset and progression of inflammation. This mechanism provides therapeutic effects for autoimmune diseases such as plaque psoriasis and radiographic axial spondyloarthritis associated with IL-17A overexpression.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Genrix Biopharmaceutical (688443.SH): Sailiqi Monoclonal Antibody Injection Included in 2025 National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Genrix Biopharmaceutical (688443.SH): Sailiqi Monoclonal Antibody Injection Included in 2025 National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-07 16:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SH) announced that its self-developed Sailiqi Monoclonal Antibody Injection (Jinlixi) has been successfully included in the National Reimbursement Drug List (NRDL) for basic medical insurance, maternity insurance, and work-related injury insurance. The updated NRDL will take effect on January 1, 2026.</p>\n<p>Sailiqi Monoclonal Antibody Injection is a company-developed recombinant fully human anti-IL-17A monoclonal antibody, classified as a Class I therapeutic biological product. It targets IL-17A, specifically binding to the IL-17A protein in serum and blocking its interaction with IL-17RA, thereby inhibiting the onset and progression of inflammation. This mechanism provides therapeutic effects for autoimmune diseases such as plaque psoriasis and radiographic axial spondyloarthritis associated with IL-17A overexpression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1199986475","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199986475","pubTimestamp":1765095732,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SH) announced that its self-developed Sailiqi Monoclonal Antibody Injection (Jinlixi) has been successfully included in the National Reimbursement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688443":"智翔金泰","BK0239":"医药制造"},"translate_title":"重庆Genrix生物制药（688443.SH）：赛力奇单抗注射液纳入2025年国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688443":1},"content_text":"Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SH) announced that its self-developed Sailiqi Monoclonal Antibody Injection (Jinlixi) has been successfully included in the National Reimbursement Drug List (NRDL) for basic medical insurance, maternity insurance, and work-related injury insurance. The updated NRDL will take effect on January 1, 2026.\nSailiqi Monoclonal Antibody Injection is a company-developed recombinant fully human anti-IL-17A monoclonal antibody, classified as a Class I therapeutic biological product. It targets IL-17A, specifically binding to the IL-17A protein in serum and blocking its interaction with IL-17RA, thereby inhibiting the onset and progression of inflammation. This mechanism provides therapeutic effects for autoimmune diseases such as plaque psoriasis and radiographic axial spondyloarthritis associated with IL-17A overexpression.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199986475","isCrawlerRequest":true}